The Healthcare company, Canopy Growth Corporation (WEED), has received a rating update from a Wall Street analyst today. Analyst John Chu from Desjardins reiterated a Hold rating, with a C$63 price target.
According to TipRanks.com, Chu is ranked #4675 out of 5208 analysts.
Currently, the analyst consensus on Canopy Growth Corporation is a Moderate Buy with an average price target of C$78.33, which is a 50.7% upside from current levels. In a report released today, BMO Capital also maintained a Hold rating on the stock.
.
The company has a one-year high of C$76.68 and a one-year low of C$31.81. Currently, Canopy Growth Corporation has an average volume of 2.18M.
Canopy Growth Corp. engages in the production and sale of medical cannabis. The company offers products including oils and concentrates, soft gel capsules, and hemp. It focuses on the treatment of chronic pain, seizures, muscle spasms, nausea, and loss of appetite.
The company’s shares closed on Monday at C$51.99.
